New MRI Methods Applied to Heart Failure With Preserved Ejection Fraction (HFpEF)

Conditions

• MRI Scans

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Accepted

Interventions

• Adenosine — DRUG
  Adenosine: 0.14mg/kg/min for 6 min. IV injection for MRI perfusion
• Regadenoson — DRUG
  0.4mg in 5ml, given as a rapid (10 seconds) IV injection for MRI perfusion.
• O-15 labeled radioactive water — DRUG
  O-15 labeled radioactive water: Up to 50mCi IV injection at rest and again at hyperemia for PET Imaging
• MRI — DEVICE
  Pass dynamic contrast enhanced MRI scans will be performed at rest and during hyperemia caused by either adenosine infusion or regadenoson
• PET Imaging — DEVICE
  Quantitative PET imaging with O-15 labeled radioactive water will be given at a different day

Study Details

This study's main specific aims are; 1. To develop robust acquisition and reconstruction methods specifically for the study of microvascular cardiac remodeling with MRI which will include very innovative quantitative perfusion methods, as well as fibrosis quantification, longitudinal strain, and phase contrast imaging for flow. 2. Test the new methods for identifying the clinical task of characterizing HFpEF.

Key Dates

Start date

Mar 3, 2017

Status verified

Jul 2026

Primary completion

Mar 3, 2027

Completion

Mar 3, 2027

Study Design

Enrollment

100 participants (estimated)

Allocation

NA

Intervention model

SINGLE_GROUP

Primary purpose

HEALTH_SERVICES_RESEARCH

Arms

• Experimental: MRI vs.PET with/without Cardiac disease
  Adenosine Regadenoson O-15 Labeled radioactive water MRI PET Imaging

Primary Outcome Measure

Myocardial perfusion measured with MRI [ Time Frame: Time in the scanner to be 60-90 minutes. ]

Central Contacts

• Olivia Pratt, BS
  801-585-6142
  [email protected]
• Collin Arsenault, BS.
  801-587-8638
  [email protected]

Locations (1)

Find similar trials in Salt Lake City, UT